

DAFTAR PUSTAKA

- Amalia, A., & Suardiana, I. K. (2025). The Role of Pharmacoeconomics in Determining Treatment Selection in Indonesia: A Scoping Review. *Journal Pharmaceutical Science and Application*, 7(1), 40-50.
- Andriani, M., Fudholi, A. F., & Andayani, T. (2019). *Analisis biaya terapi pada penyakit kanker paru rawat inap Jaminan Kesehatan Nasional di RSI Sultan Agung Semarang* (Tesis). Universitas Gadjah Mada.
- Apple, J., DerSarkissian, M., Shah, A., Chang, R., Chen, Y., He, X., & Chun, J. (2023). Economic burden of early-stage non-small-cell lung cancer: an assessment of healthcare resource utilization and medical costs. *Journal of comparative effectiveness research*, 12(11), e230107.
- Araghi, M., Mannani, R., Heidarnajad Maleki, A., Hamidi, A., Rostami, S., Safa, S. H., Faramarzi, F., Khorasani, S., Alimohammadi, M., Tahmasebi, S., & Akhavan-Sigari, R. (2023). Recent advances in non-small cell lung cancer targeted therapy; an update review. *Cancer cell international*, 23(1), 162.
- Arooj, P., Hassan, M., Rai, H., Zaki, I., Syred, K., Hadden, R., Farrugia, J., Taylor, L., Howell, T., Nicholson, T., Corcoran, J., & Daneshvar, C. (2025). A comparison of pulmonologist-led biopsy techniques for histological subtyping and molecular profiling in non-small-cell lung cancer. *Respiratory medicine*, 250, 108535.
- Asmara, O. D., Tenda, E. D., Singh, G., Pitoyo, C. W., Rumende, C. M., Rajabto, W., Ananda, N. R., Trisnawati, I., Budiyo, E., Thahadian, H. F., Boerma, E. C., Faisal, A., Hutagaol, D., Soeharto, W., Radityamurti, F., Marfiani, E., Romadhon, P. Z., Kholis, F. N., Suryadinata, H., Soeroto, A. Y., ... van Geffen, W. H. (2023). Lung Cancer in Indonesia. *Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer*, 18(9), 1134–1145.
- Asmara, O. D., Hardavella, G., Ramella, S., Petersen, R. H., Tietzova, I., Boerma, E. C., Tenda, E. D., Bouterfas, A., Heuvelmans, M. A., & van Geffen, W. H. (2024). Stage III NSCLC treatment options: too many choices. *Breathe (Sheffield, England)*, 20(3), 240047.
- Awosika, A. O., Farrar, M. C., Jacobs, T. F. (2023). *Paclitaxel*. In StatPearls. StatPearls Publishing.
- Batihani, G., Ceylan, K. C., Usluer, O., & Kaya, Ş. Ö. (2020). Video-Assisted Thoracoscopic Surgery vs Thoracotomy for Non-Small Cell Lung Cancer Greater Than 5 cm: Is VATS a feasible approach for large tumors? *Journal of cardiothoracic surgery*, 15(1), 261.
- Bejckova, A., Marel, M., Chladkova, Z., Fila, L., Casas-Mendez, L. F., Vencliceck, O., Jakubec, P., Cernovska, M., Hrciarik, M., Krejci, J., Domecky, P., & Svaton, M. (2025). Comparison of the efficacy of cisplatin and carboplatin in combination with etoposide in firstline treatment of extensive-stage small cell lung cancer in real-world practice in the Czech Republic - a retrospective analysis of patients from the LUCAS project. *Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia*, 169(3), 218–225.

- Biyanto, F. (2025). Tantangan dalam penghitungan biaya satuan layanan (unit cost) rumah sakit di Indonesia. *Juremi: Jurnal Riset Ekonomi*, 5(2), 587–602.
- Borczuk A. C. (2024). Molecular Testing in Lung Cancer: Recommendations and Update. *Surgical pathology clinics*, 17(2), 307–320.
- Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: a cancer journal for clinicians*, 74(3), 229–263.
- Buja, A., Rivera, M., De Polo, A., Brino, E. D., Marchetti, M., Scioni, M., Pasello, G., Bortolami, A., Rebba, V., Schiavon, M., Calabrese, F., Mandoliti, G., Baldo, V., & Conte, P. (2021). Estimated direct costs of non-small cell lung cancer by stage at diagnosis and disease management phase: A whole-disease model. *Thoracic cancer*, 12(1), 13–20.
- Buja, A., Rugge, M., Di Pumpo, M., Zorzi, M., Rea, F., Pantaleo, I., Scroccaro, G., Conte, P., Rigon, L., Arcara, G., Pasello, G., & Guarneri, V. (2025). Healthcare Costs by Comorbidity Patterns in Lung Cancer Patients. *Cancers*, 17(16), 2682.
- Buja, A., Di Pumpo, M., Rugge, M., Zorzi, M., Rea, F., Pantaleo, I., Scroccaro, G., Conte, P., Rigon, L., Arcara, G., Pasello, G., Guarneri, V., & Rete Oncologica Veneta and Periplo Foundation (2025). Patterns of Comorbidities in Lung Cancer Patients and Survival. *Cancers*, 17(9), 1577.
- Buja, A., Rugge, M., Bortolami, A., Zorzi, M., Rea, F., Zanovello, A., Scroccaro, G., Conte, P., Pasello, G., Guarneri, V., On Behalf of Rete Oncologica Veneta, & Periplo Foundation (2025). NON-SMALL-CELL LUNG CANCER: Real-World Population-Based Cohorts' Study. *Cancers*, 17(4), 648.
- Cai, B., Fulcher, N., Boyd, M., & Spira, A. (2021). Clinical outcomes and resource utilization after surgical resection with curative intent among patients with non-small cell lung cancer treated with adjuvant therapies in a community oncology setting: A real-world retrospective observational study. *Thoracic cancer*, 12(14), 2055–2064.
- Cao, W., Tang, Q., Zeng, J., Jin, X., Zu, L., & Xu, S. (2023). A review of biomarkers and their clinical impact in resected early-stage non-small-cell lung cancer. *Cancers*, 15(18), 4561.
- Casal-Mouriño, A., Ruano-Ravina, A., Lorenzo-González, M., Rodríguez-Martínez, Á., Giraldo-Osorio, A., Varela-Lema, L., Pereiro-Brea, T., Barros-Dios, J. M., Valdés-Cuadrado, L., & Pérez-Ríos, M. (2021). Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival. *Translational lung cancer research*, 10(1), 506–518.
- Chen, Q., Ying, S., Qin, J., & Zhang, L. (2024). Optimization of treatment strategies for elderly patients with advanced non-small cell lung cancer. *Frontiers in oncology*, 14, 1384906.
- Cheng, W. C., Shen, Y. C., Chen, C. L., Liao, W. C., Chen, C. H., Chen, H. J., Tu, C. Y., & Hsia, T. C. (2023). Bevacizumab versus Ramucirumab in EGFR-Mutated Metastatic Non-Small-Cell Lung Cancer Patients: A Real-World Observational Study. *Cancers*, 15(3), 642.

- Cicin, I., Oksuz, E., Karadurmus, N., Malhan, S., Gumus, M., Yilmaz, U., Cansever, L., Cinarka, H., Cetinkaya, E., Kiyik, M., Ozet, A., Lung Cancer Report Study Group Turkey, Turkish Society of Lung Cancer, Lung Health and Intensive Care Association, University of Health Sciences, Turkish Society of Medical Oncology, National Cancer Institute, & Turkish Respiratory Society. (2021). Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective. *Health economics review*, 11(1), 22.
- Clark, S. B., & Alsubait, S. (2023). *Non-Small Cell Lung Cancer*. In StatPearls. StatPearls Publishing.
- Criner, G. J., Agusti, A., Borghaei, H., Friedberg, J., Martinez, F. J., Miyamoto, C., Vogelmeier, C. F., & Celli, B. R. (2022). Chronic Obstructive Pulmonary Disease and Lung Cancer: A Review for Clinicians. *Chronic obstructive pulmonary diseases (Miami, Fla.)*, 9(3), 454–476.
- Detterbeck, F. C. (2018). The eighth edition TNM stage classification for lung cancer. *The Journal of Thoracic and Cardiovascular Surgery*, 155(1), 356–359.
- Ding, R., Zhu, D., He, P., Ma, Y., Chen, Z., & Shi, X. (2020). Comorbidity in lung cancer patients and its association with medical service cost and treatment choice in China. *BMC cancer*, 20(1), 250.
- Dunne, E. G., Fick, C. N., & Jones, D. R. (2023). Mediastinal Staging in Non-Small-Cell Lung Cancer: Saying Goodbye to Mediastinoscopy. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*, 41(22), 3785–3790.
- Ferlay, J., Ervik, M., Lam, F., Laversanne, M., Colombet, M., Mery, L., Piñeros, M., Znaor, A., Soerjomataram, I., & Bray, F. (2024). Global Cancer Observatory: Cancer Today (GLOBOCAN 2022, version 1.1). International Agency for Research on Cancer.
- Gálffy, G., Morócz, É., Korompay, R., Hécz, R., Bujdosó, R., Puskás, R., Lovas, T., Gáspár, E., Yahya, K., Király, P., & Lohinai, Z. (2024). Targeted therapeutic options in early and metastatic NSCLC-overview. *Pathology oncology research: POR*, 30, 1611715.
- Garitaonandia, Y., Calvo, V., Redondo, I., Uribarren, M., Ospina Serrano, A. V., Collazo, A., Blanco, M., & Provencio, M. (2023). Docetaxel as a subsequent line after progression to platinum-based chemotherapy and immunotherapy. *Journal of Clinical Oncology*, 41(16_suppl), e21197.
- Hisakane, K., Tozuka, T., Takahashi, S., Taniuchi, N., Nishijima, N., Atsumi, K., Okano, T., Seike, M., & Hirose, T. (2023). Platinum-combination chemotherapy with or without immune-checkpoint inhibitor in patients with postoperative recurrent non-small cell lung cancer previously treated with adjuvant platinum-doublet chemotherapy: A multicenter retrospective study. *Thoracic cancer*, 14(21), 2069–2076.
- Houda, I., Naves, D., Ulas, E. B., Lissenberg-Witte, B. I., Barlo, N. P., Kastelijjn, E. A., Bouhaddou, H., Shaikh, R., Dickhoff, C., Radonic, T., Schneiders, F. L., Senan, S., Damhuis, R. A. M., & Bahce, I. (2025). Survival outcomes with carboplatin versus cisplatin and the impact of COVID-19 on platinum

- choice: A nationwide Netherlands registry study in small cell lung cancer patients (CACIS). *European journal of cancer (Oxford, England: 1990)*, 230, 116042.
- Hsu, R., Chen, D., Xia, B., Feldman, R., Cozen, W., Raez, L. E., Borghaei, H., Kim, C., Nagasaka, M., Mamdani, H., Vanderwalde, A. M., Lopes, G., Socinski, M. A., Wozniak, A. J., Spira, A. I., Liu, S. V., & Nieva, J. J. (2023). Impact of gender and mutational differences in hormone receptor expressing non-small cell lung cancer. *Frontiers in oncology*, 13, 1215524.
- Jang, J. Y., Kim, D., Im, E., & Kim, N. D. (2025). Etoposide as a Key Therapeutic Agent in Lung Cancer: Mechanisms, Efficacy, and Emerging Strategies. *International journal of molecular sciences*, 26(2), 796.
- Jeon, D. S., Kim, J. W., Kim, S. G., Kim, H. R., Song, S. Y., Lee, J. C., Ji, W., Choi, C. M., Kim, H. C., & Korean Association for Lung Cancer, South Korea Central Cancer Registry (2022). Sex differences in the characteristics and survival of patients with non-small-cell lung cancer: A retrospective analytical study based on real-world clinical data of the Korean population. *Thoracic cancer*, 13(18), 2584–2591.
- Jovanoski, N., Abogunrin, S., Di Maio, D., Belleli, R., Hudson, P., Bhaddi, S., & Jones, L. G. (2023). Systematic Literature Review to Identify Cost and Resource Use Data in Patients with Early-Stage Non-small Cell Lung Cancer (NSCLC). *PharmacoEconomics*, 41(11), 1437–1452.
- Kementerian Kesehatan Republik Indonesia. (2023). *Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/1438/2023 tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Kanker Paru*. Jakarta: Kementerian Kesehatan Republik Indonesia.
- Kementerian Kesehatan Republik Indonesia. (2023). *Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/2197/2023 tentang Formularium Nasional*. Jakarta: Kementerian Kesehatan Republik Indonesia.
- Khasanah, F. N. (2023). *Cost effectiveness analysis of NSCLC without EGFR mutation at RSUP Dr. Kariadi Semarang* (Skripsi). Universitas Muhammadiyah Purwokerto.
- Khopade, A. J., Shah, M. D., Borole, B. S., & Burade, V. (2025). Antitumor Efficacy of Paclitaxel Injection Concentrate for Nanodispersion in Patient-Derived Breast, Head and Neck, and Non-Small Cell Lung Cancer Mouse Xenografts. *AAPS PharmSciTech*, 26(5), 150.
- Kim, C. S., Gasalberti, D. P., & Jeter, M. D. (2024). *Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer*. In StatPearls. StatPearls Publishing.
- Laguna, J. C., Tagliamento, M., Lambertini, M., Hiznay, J., & Mezquita, L. (2024). Tackling Non-Small Cell Lung Cancer in Young Adults: From Risk Factors and Genetic Susceptibility to Lung Cancer Profile and Outcomes. *American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting*, 44(3), e432488.
- Lau, S. C. M., Pan, Y., Velcheti, V., & Wong, K. K. (2022). Squamous cell lung cancer: Current landscape and future therapeutic options. *Cancer cell*, 40(11), 1279–1293.

- Lin, Z., Liu, H., Li, W., & Zhang, K. (2025). Efficacy and safety of first-line treatment options for advanced non-small cell lung cancer: A retrospective study. *Medicine*, 104(30), e43300.
- Liu, X., Liu, X. X., Shao, W., Zhou, Y., Zhang, J., Zhao, C., & Shen, C. (2024). Cost-effectiveness analysis of camrelizumab plus paclitaxel and carboplatin versus sintilimab plus gemcitabine and cisplatin or carboplatin for the first-line treatment of local advanced or metastatic squamous NSCLC in Chinese mainland. *Frontiers in Pharmacology*, 15, 1356725.
- Lv, Y., Cao, Z., Pan, J., Gong, E., Zheng, H., & Cai, X. (2021). Pemetrexed-based first-line chemotherapy had particularly prominent objective response rate for advanced NSCLC: A network meta-analysis. *Open medicine (Warsaw, Poland)*, 16(1), 183–191. <https://doi.org/10.1515/med-2021-0202>
- Ma, H., Yao, D., Cheng, J., Wang, W., Liu, B., Yu, Y., Xing, W., & Qin, J. (2022). Older patients more likely to die from cancer-related diseases than younger with stage IA non-small cell lung cancer: a SEER database analysis. *Journal of thoracic disease*, 14(6), 2178–2186.
- Madae'en, S. S., Salem, A. A., Ararawi, N. S., Ramzi, E. J., Aloueedat, R. F., Saabenh, A. M., Allouzi, D. A., Abuoudeh, R. H., Hnaif, O. E., Musa, L. M., Alshdaifat, S. H., Al-Tanashat, A. J., Almasa'afeh, H. Y., & Abuallaban, S. M. (2025). Comparative Cost Analysis for Direct Medical Costs of Protocol Administration of Non-Small Cell Lung Cancer Treatment Regimens in Curative Intent: A Micro-Costing Study in Jordan. *ClinicoEconomics and outcomes research: CEOR*, 17, 455–471.
- May, L., Shows, K., Nana-Sinkam, P., Li, H., & Landry, J. W. (2023). Sex Differences in Lung Cancer. *Cancers*, 15(12), 3111.
- Mennini, F. S., & Gitto, L. (2022). Approaches to estimating indirect costs in healthcare: Motivations for choice. *Journal of European Economy*, 21(1), 17–45.
- Mina, S. A., Shanshal, M., Leventakos, K., & Parikh, K. (2025). Emerging Targeted Therapies in Non-Small-Cell Lung Cancer (NSCLC). *Cancers*, 17(3), 353.
- Mountzios G. (2025). Immunotherapy With or Without Chemotherapy in Advanced NSCLC-A Delicate Balance of Harm and Benefit. *JAMA oncology*, 11(7), 716–717.
- Mukaida, N., Nosaka, T., Nakamoto, Y., & Baba, T. (2019). Lung Macrophages: Multifunctional Regulator Cells for Metastatic Cells. *International Journal of Molecular Sciences*, 20(1), 116.
- Myers, D. J., & Wallen, J. M. (2023). *Lung adenocarcinoma*. In StatPearls. StatPearls Publishing.
- Northern Cancer Alliance. (2018). *Carboplatin and paclitaxel treatment protocol (CRP14 L014 v1.5)*. National Health Service.
- Northern Cancer Alliance. (2018). *Cisplatin pemetrexed chemotherapy protocol (CRP09 L0016 v1.4)*. National Health Service.
- National Cancer Institute. (2025). *Non-Small Cell Lung Cancer Treatment (PDQ®): Health professional version*. National Cancer Institute.

- National Comprehensive Cancer Network. (2025). *NCCN guidelines for patients: Early and locally advanced non-small cell lung cancer* (Version 2025). Fort Washington, PA: National Comprehensive Cancer Network.
- National Comprehensive Cancer Network. (2025). *NCCN guidelines for patients: Metastatic non-small cell lung cancer* (Version 2025). Fort Washington, PA: National Comprehensive Cancer Network.
- Park D. (2024). Advanced Bronchoscopic Diagnostic Techniques in Lung Cancer. *Tuberculosis and respiratory diseases*, 87(3), 282–291.
- Parveen, S. (2022). Platinum-based cancer chemotherapeutics: Recent trends and future perspectives. *Current Chinese Science*, 2(4), 275-293.
- Permsuwan, U., Thongprasert, S., & Sirichanchuen, B. (2020). Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand. *Value in health regional issues*, 21, 9–16.
- Pham-Danis, C., Chia, S. B., Scarborough, H. A., Danis, E., Nemkov, T., Zaberezhnyy, V., Christenson, J. L., Kleczko, E. K., Navarro, A., Goodspeed, A., Bonney, E. A., Dinarello, C. A., Marchetti, C., Nemenoff, R. A., Hansen, K. C., & DeGregori, J. (2025). Inflammation Promotes Aging-Associated Oncogenesis in the Lung. *Aging and cancer*, 6(1), 3–18.
- Pradelli, L., & Wertheimer, A. (Eds.). (2022). *Pharmacoeconomics: Principles and practice*. Torino: SEEd.
- Raza, M., Gowda, A. M. (2025). *Platinum Hypersensitivity and Toxicity*. In StatPearls. StatPearls Publishing
- Rianyta, R., Louisa, M., Syahrudin, E., & Soetikno, V. (2021). Observational Study of Paclitaxel-Carboplatin versus Pemetrexed-Carboplatin for Advanced Pulmonary Adenocarcinoma at Single-Centre in Indonesia. *eJournal Kedokteran Indonesia*, 178-86.
- Riely, G. J., Wood, D. E., Ettinger, D. S., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., DeCamp, M., Desai, A. P., Dilling, T. J., Dowell, J., Durm, G. A., Gettinger, S., Grotz, T. E., Gubens, M. A., Juloori, A., Lackner, R. P., ... Hang, L. (2024). Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology. *Journal of the National Comprehensive Cancer Network: JNCCN*, 22(4), 249–274.
- Republik Indonesia. (2024). *Peraturan Presiden Republik Indonesia Nomor 59 Tahun 2024 tentang Perubahan Ketiga atas Peraturan Presiden Nomor 82 Tahun 2018 tentang Jaminan Kesehatan*. Jakarta: Sekretariat Negara.
- Restyana, A., Faradiba, Farida, U., Dewi Wahyuni, K. S. P., Pambudi, R. S., Toyo, E. M., Admaja, W., Hendra, G. A., Prasetyo, E. Y., & Noviyani, R. (2024). *Fakmakoeonomi*. Malang: Future Science Publisher.
- Roberts, M. E., Rahman, N. M., Maskell, N. A., Bibby, A. C., Blyth, K. G., Corcoran, J. P., Edey, A., Evison, M., de Fonseka, D., Hallifax, R., Harden, S., Lawrie, I., Lim, E., McCracken, D., Mercer, R., Mishra, E. K., Nicholson, A. G., Noorzad, F., Opstad, K. S., Parsonage, M., ... Walker, S. (2023). British Thoracic Society Guideline for pleural disease. *Thorax*, 78(11), 1143–1156.

- Robot, R. Y., Durry, M. F., & Kairupan, C. F. (2021). Morfologi, patogenesis, dan imunoterapi kanker paru tipe adenokarsinoma. *Medical Scope Journal*, 3(1), 74–82.
- Saller, J., & Boyle, T. A. (2022). Molecular Pathology of Lung Cancer. *Cold Spring Harbor perspectives in medicine*, 12(3), a037812.
- Seung, S. J., Hurry, M., Hassan, S., Walton, R. N., & Evans, W. K. (2019). Cost-of-illness study for non-small-cell lung cancer using real-world data. *Current oncology (Toronto, Ont.)*, 26(2), 102–107.
- Sittimart, M., Rattanaipapong, W., Mirelman, A. J., Hung, T. M., Dabak, S., Downey, L. E., Jit, M., Teerawattananon, Y., & Turner, H. C. (2024). An overview of the perspectives used in health economic evaluations. *Cost effectiveness and resource allocation: C/E*, 22(1), 41.
- Sugiyono. (2013). *Metode penelitian kuantitatif, kualitatif, dan R&D*. Bandung: Alfabeta. ISBN 979-8433-64-0.
- Suraya, R., Tachihara, M., Nagano, T., Nishimura, Y., & Kobayashi, K. (2022). Immunotherapy in Advanced Non-Small Cell Lung Cancers: Current Status and Updates. *Cancer management and research*, 14, 2079–2090.
- Szupryczyński, K., Czeleń, P., Jeliński, T., & Szefer, B. (2024). What is the reason that the pharmacological future of chemotherapeutics in the treatment of lung cancer could be Most closely related to nanostructures? Platinum drugs in therapy of non-small and small cell lung cancer and their unexpected, possible interactions. The review. *International Journal of Nanomedicine*, 9503-9547.
- Tahayneh, K., Idkedek, M., & Abu Akar, F. (2025). NSCLC: Current Evidence on Its Pathogenesis, Integrated Treatment, and Future Perspectives. *Journal of clinical medicine*, 14(3), 1025.
- Thames Valley Cancer Alliance. (2022). *Paclitaxel cisplatin protocol*. National Health Service.
- Tsvetkova, D., & Ivanova, S. (2022). Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases. *Molecules (Basel, Switzerland)*, 27(8), 2466.
- Uhm, S. J., Meszaros, E., Hammonds, K., Patel, I., & Herrington, J. D. (2021). Characterizing the impact of magnesium and potassium-supplemented hydration with cisplatin and the subsequent electrolyte replacement requirements. *Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners*, 27(5), 1125–1131.
- Vashistha, V., Garg, A., Iyer, H., Jain, D., Madan, K., Hadda, V., Guleria, R., & Mohan, A. (2021). A comprehensive comparison between young and older-age non-small cell lung cancer patients at a public referral centre in Delhi, India. *Ecancermedicalscience*, 15, 1223.
- Wahyudi, Avianti, W., Martin, A., Jumali, Andriyani, N., Prihatiningsih, D., Misesani, D., Fahrudin, Yufrinalis, M., Mbari, M. A. F., Ningsih, A. G., Yulianto, A., Rokhman, M. T. N., Haqiyah, A., & Sukwika, T. (2023). *Metode penelitian (Dasar praktik dan penerapan berbasis ICT)*. Deli Serdang: PT. Mifandi Mandiri Digital. ISBN 978-623-88562-4-4.

- Wang, C., Lu, D., Cronin-Fenton, D., Huang, C., Liew, Z., Wei, D., Qin, G., Yu, Y., & Li, J. (2022). Cardiovascular disease and risk of lung cancer incidence and mortality: A nationwide matched cohort study. *Frontiers in oncology*, 12, 950971.
- Wang, Y., Pond, G., Gafni, A. J., Kong, C. Y., & Ellis, P. M. (2025). Cost Disparities with Age in the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC) in Ontario, Canada. *Current oncology (Toronto, Ont.)*, 32(6), 346.
- Wulandari, A., Monalisa, S., & Zaini, J. (2019). Analisis biaya kemoterapi lini pertama pada pasien kanker paru di Rumah Sakit Persahabatan Jakarta Timur periode tahun 2016. *Jurnal Ilmu Kefarmasian Indonesia*, 17(1), 85–92.
- Xu, W., Liu, X., Yan, C., Abdurahmane, G., Lazibiek, J., Zhang, Y., & Cao, M. (2024). The prognostic value and model construction of inflammatory markers for patients with non-small cell lung cancer. *Scientific Reports*, 14(1), 7568.
- Yang, J. C. H., Lee, D. H., Lee, J. S., Fan, Y., De Marinis, F., Okamoto, I., ... Lu, S. (2023). Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study. *Journal of Clinical Oncology*, 41.
- Yaskolko, M., Liu, C., Barsouk, A., Sussman, J. H., & Barsouk, A. A. (2025). Disparities in Non-Small Cell Lung Cancer (NSCLC) by Age, Sex, and Race: A Systematic Review and Meta-Analysis of Immune Checkpoint Inhibitor (ICI) Trials. *Cancers*, 18(1), 128.
- Yatabe Y. (2024). Molecular pathology of non-small cell carcinoma. *Histopathology*, 84(1), 50–66.
- Yonatan, A. Z. (2024, 16 Mei). Ada lebih dari 269 juta peserta BPJS Kesehatan di 2024. *GoodStats Data*. https://data.goodstats.id/statistic/ada-lebih-dari-269-juta-peserta-bpjs-kesehatan-di-2024-xHnLi?utm_source=chatgpt.com
- Yousefi, M., Jalilian, H., Heydari, S., Seyednejad, F., & Mir, N. (2023). Cost of Lung Cancer: A Systematic Review. *Value in health regional issues*, 33, 17–26.
- Yuliasuti, F., Andayani, T. M., Endarti, D., & Kristina, S. A. (2023). Breast, cervical, and lung cancer: A comparison of real healthcare costs and INA-CBGs rates in the era of national health insurance. *Pharmacy practice*, 21(1), 2768.
- Yusoh, N. A., Ahmad, H., Vallis, K. A., & Gill, M. R. (2025). Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies. *Medical Oncology*, 42(7), 262.
- Zeng, J., Shi, D., He, D., Dong, W., Yang, Z., & Chen, Y. (2025). Comorbidity of hypertension and lung cancer: interplay of genetics and environment. *Discover oncology*, 16(1), 1548.
- Zhang, C., Xu, C., Gao, X., & Yao, Q. (2022). Platinum-based drugs for cancer therapy and anti-tumor strategies. *Theranostics*, 12(5), 2115–2132.

- Zhang, S., Liu, L., Shi, S., He, H., Shen, Q., Wang, H., Qin, S., Chang, J., & Zhong, R. (2024). Bidirectional Association Between Cardiovascular Disease and Lung Cancer in a Prospective Cohort Study. *Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer*, 19(1), 80–93.
- Zhao, Z., Yang, C., & Li, J. (2025). Pemetrexed and platinum with or without pembrolizumab for advanced non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis. *Clinical & translational oncology: official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico*, 27(5), 2024–2036.
- Zhu, D., Shi, X., Nicholas, S., Ma, Y., & He, P. (2021). Estimated annual prevalence, medical service utilization and direct costs of lung cancer in urban China. *Cancer medicine*, 10(8), 2914–2923.